ESSA Pharma Inc. financial data

Symbol
EPIX on Nasdaq
Industry
Pharmaceutical Preparations
Location
Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada
State of incorporation
British Columbia, Canada
Fiscal year end
September 30
Latest financial report
10-K - Q3 2024 - Dec 17, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.71K % -28.9%
Debt-to-equity 2.95 % +49.9%
Return On Equity -21.6 % -25%
Return On Assets -21 % -23.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.4M shares +0.56%
Common Stock, Shares, Outstanding 44.4M shares +0.65%
Entity Public Float 377M USD +378%
Common Stock, Value, Issued 280M USD +0.61%
Weighted Average Number of Shares Outstanding, Basic 44.3M shares +0.43%
Weighted Average Number of Shares Outstanding, Diluted 44.3M shares +0.43%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 21.2M USD -0.54%
General and Administrative Expense 13.2M USD +22.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -7.23M USD +0.89%
Income Tax Expense (Benefit) 1.6K USD
Net Income (Loss) Attributable to Parent -28.5M USD -7.38%
Earnings Per Share, Basic -0.64 USD/shares -6.67%
Earnings Per Share, Diluted -0.64 USD/shares -6.67%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 104M USD +208%
Assets, Current 128M USD -14.3%
Operating Lease, Right-of-Use Asset 295K USD +334%
Assets 128M USD -14.1%
Accounts Payable, Current 2.4M USD +18.5%
Accrued Liabilities, Current 172K USD -79.7%
Liabilities, Current 3.3M USD -5.55%
Operating Lease, Liability, Noncurrent 205K USD
Liabilities 3.51M USD +0.32%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.06M USD +2.69%
Retained Earnings (Accumulated Deficit) -208M USD -15.9%
Stockholders' Equity Attributable to Parent 125M USD -14.4%
Liabilities and Equity 128M USD -14.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.79M USD -55.1%
Net Cash Provided by (Used in) Financing Activities 197K USD +1156%
Net Cash Provided by (Used in) Investing Activities 8.23M USD
Common Stock, Shares, Issued 44.4M shares +0.65%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.64M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 104M USD +208%
Deferred Tax Assets, Valuation Allowance 50.3M USD +11.3%
Deferred Tax Assets, Gross 50.3M USD +11.3%
Operating Lease, Liability 329K USD +310%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -28.5M USD -7.22%
Lessee, Operating Lease, Liability, to be Paid 378K USD
Operating Lease, Liability, Current 124K USD +54.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 134K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 130K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 49.1K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 114K USD
Deferred Tax Assets, Operating Loss Carryforwards 49.8M USD +13.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.7K USD
Operating Lease, Payments 34.6K USD +7%
Additional Paid in Capital 54.8M USD +11.8%
Deferred Tax Assets, Net of Valuation Allowance 0 USD